|
|
|
|
|
|
by refurb
4112 days ago
|
|
|
It's not like going from an animal model to human trials or from a tiny cohort of late-stage patients to a larger more heterogenous group. Fair point. A retrospective analysis would provide some data. The problem is insurance companies have pretty high standards (at least for cancer drug that cost a lot)! |
|
|